Henlius Wins NMPA Nod to Start Trials of Novel Hyaluronidase Injection

Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) has provided an announcement.

Shanghai Henlius Biotech has received approval from China’s National Medical Products Administration for an investigational new drug application to begin a phase 1 clinical trial of HLXTE-HAase02, a recombinant human hyaluronidase injection. The company plans to initiate clinical testing in mainland China once conditions are met, positioning the asset as a platform to enhance absorption and bioavailability of subcutaneously administered drugs and to improve patient convenience.

HLXTE-HAase02 is designed to temporarily break down hyaluronic acid in subcutaneous tissue to increase injection volume and facilitate better dispersion and permeability of co-administered drugs. With around 10 similar rHuPH20-based regimens already approved globally in areas such as oncology, autoimmune, immunodeficiency and neurological diseases, Henlius’ entry into this space could bolster its competitive standing, though the company cautions there is no guarantee of successful development or commercialization.

The most recent analyst rating on (HK:2696) stock is a Buy with a HK$99.78 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.

More about Shanghai Henlius Biotech, Inc. Class H

Shanghai Henlius Biotech, Inc. is a biopharmaceutical company based in mainland China, focused on developing innovative biologic therapies. The company’s research pipeline includes oncology and immunology products, and it is expanding into enabling technologies that improve subcutaneous delivery of injectable drugs for a range of therapeutic areas.

Average Trading Volume: 980,458

Technical Sentiment Signal: Buy

Current Market Cap: HK$25.95B

For a thorough assessment of 2696 stock, go to TipRanks’ Stock Analysis page.